The discovery of receptor tyrosine kinases: targets for cancer therapy
暂无分享,去创建一个
[1] A. Riggs,et al. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. , 1977, Science.
[2] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[3] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[4] Andrius Kazlauskas,et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.
[5] A. Ullrich,et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.
[6] Jonathan A. Cooper,et al. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells , 1981, Cell.
[7] H Ueno,et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.
[8] David C. Lee,et al. An essential role for ectodomain shedding in mammalian development. , 1998, Science.
[9] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[10] A. Ullrich,et al. A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis , 1987, Molecular and cellular biology.
[11] G. Frantz,et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. , 1997, Development.
[12] A. Kaye,et al. Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. , 1988, Cancer research.
[13] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[14] P. H. Seeburg,et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes , 1985, Nature.
[15] Edouard C. Nice,et al. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.
[16] P. Seeburg,et al. The c‐sis gene encodes a precursor of the B chain of platelet‐derived growth factor. , 1984, The EMBO journal.
[17] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[18] H. Kung,et al. Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[19] Stefan Hart,et al. TACE cleavage of proamphiregulin regulates GPCR‐induced proliferation and motility of cancer cells , 2003, The EMBO journal.
[20] A. Ullrich,et al. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing , 1987, Cell.
[21] Mark R. Smith,et al. Requirement for c-ras proteins during viral oncogene transformation , 1986, Nature.
[22] T. Hunter,et al. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine , 1980, Proceedings of the National Academy of Sciences.
[23] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[24] F. Shibasaki,et al. Ash/Grb‐2, a SH2/SH3‐containing protein, couples to signaling for mitogenesis and cytoskeletal reorganization by EGF and PDGF. , 1993, The EMBO journal.
[25] A. Ullrich,et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. , 1996, Cancer research.
[26] C. Marshall,et al. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.
[27] S. Cohen,et al. The stimulation of epidermal proliferation by a specific protein (EGF). , 1965, Developmental biology.
[28] A. Ullrich,et al. Insulin-like growth factor II precursor gene organization in relation to insulin gene family , 1984, Nature.
[29] A. Ullrich,et al. A chimaeric receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth factor receptor , 1986, Nature.
[30] R. Weinberg,et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.
[31] C Collins,et al. Insulin‐like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. , 1986, The EMBO journal.
[32] A. Ullrich,et al. Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.
[33] A. Ullrich,et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling , 1992, Cell.
[34] A. Ullrich,et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.
[35] Kenneth J. Hillan,et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.
[36] R. Weinberg,et al. Identification of a nucleotide exchange-promoting activity for p21ras. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[37] Martin R. Schneider,et al. PTK 787 / ZK 222584 , a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases , Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration , 2000 .
[38] A. Ullrich,et al. Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor , 1983, Nature.
[39] P. Seeburg,et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.
[40] A. Ullrich,et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.
[41] T Pawson,et al. Src homology region 2 domains direct protein-protein interactions in signal transduction. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[42] J. Martial,et al. Human growth hormone: complementary DNA cloning and expression in bacteria. , 1979, Science.
[43] S. Cohen,et al. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. , 1980, The Journal of biological chemistry.
[44] E. Chen,et al. Human transforming growth factor-α: Precursor structure and expression in E. coli , 1984, Cell.
[45] W. Rutter,et al. Rat insulin genes: construction of plasmids containing the coding sequences. , 1977, Science.
[46] R. Levi‐montalcini. EFFECTS OF MOUSE TUMOR TRANSPLANTATION ON THE NERVOUS SYSTEM , 1952, Annals of the New York Academy of Sciences.
[47] K. Herrup,et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.
[48] G. Carpenter,et al. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro , 1978, Nature.
[49] C R King,et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.
[50] J. Schlessinger,et al. Ligand-independent tyrosine phosphorylation of EGF receptor and the erbB-2/neu proto-oncogene product is induced by hyperosmotic shock. , 1989, Oncogene.
[51] Giovanni Parmigiani,et al. Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Nature Reviews Cancer.
[52] R. Peek,et al. cag+ Helicobacter pylori Induce Transactivation of the Epidermal Growth Factor Receptor in AGS Gastric Epithelial Cells* , 2001, The Journal of Biological Chemistry.
[53] Inder M. Verma,et al. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus , 1986, Nature.
[54] A. Ullrich,et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.
[55] J. Mestan,et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.
[56] A. Wolfman,et al. A cytosolic protein catalyzes the release of GDP from p21ras. , 1990, Science.
[57] Jae-Hoon Kim,et al. Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.
[58] P. Seeburg,et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.
[59] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[60] F. McCormick. How receptors turn Ras on , 1993, Nature.
[61] Philippe Shubik,et al. VEGF and the quest for tumour angiogenesis factors , 2022 .
[62] L. Silengo,et al. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion‐dependent cell survival , 1998, The EMBO journal.
[63] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[64] David C. Lee,et al. Defective valvulogenesis in HB‐EGF and TACE‐null mice is associated with aberrant BMP signaling , 2003, The EMBO journal.
[65] A. Burgess,et al. Anti-sense transforming growth factor alpha oligonucleotides inhibit autocrine stimulated proliferation of a colon carcinoma cell line. , 1992, Molecular biology of the cell.
[66] Z. Kam,et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.
[67] H. Hihara,et al. A new avian erythroblastosis virus, AEV-H, carries erbB gene responsible for the induction of both erythroblastosis and sarcomas , 1983, Cell.
[68] J. Mendelsohn,et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. , 1983, Molecular biology & medicine.
[69] Hiroshi Asanuma,et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.
[70] J. Schlessinger,et al. Signal transduction by allosteric receptor oligomerization. , 1988, Trends in biochemical sciences.
[71] P. Humphrey,et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[72] C. Kahn,et al. Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system , 1982, Nature.
[73] T. Hunter,et al. An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates , 1979, Cell.
[74] B. Mayer,et al. Binding of transforming protein, P47gag-crk, to a broad range of phosphotyrosine-containing proteins. , 1990, Science.
[75] J Folkman,et al. Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.
[76] D. Dimitrov,et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.
[77] J. Woodburn,et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines , 2005, Breast Cancer Research and Treatment.
[78] Janet Rossant,et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.
[79] G. Carpenter,et al. Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. , 1975, The Journal of biological chemistry.
[80] Morag Park,et al. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. , 2003, Cancer cell.
[81] T. Takenawa,et al. Cloning of ASH, a ubiquitous protein composed of one Src homology region (SH) 2 and two SH3 domains, from human and rat cDNA libraries. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[82] T. Hunter,et al. Phospholipase C-γ is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro , 1989, Cell.
[83] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[84] J. Mendelsohn,et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[85] A. Levitzki,et al. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors , 1988, Science.
[86] S. Cohen,et al. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. , 1962, The Journal of biological chemistry.
[87] S. Cohen,et al. Purification and properties of a nerve growth-promoting factor isolated from mouse sarcoma 180. , 1957, Cancer research.
[88] R. Derynck,et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor , 1995, Nature.
[89] Charles Eigenbrot,et al. Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor , 1997, Cell.
[90] A. Ullrich,et al. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors , 1996, Nature.
[91] Kohjiro Ueki,et al. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone , 1997, Nature.
[92] Nicole Nelson,et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.
[93] W. Langdon,et al. Tyrosine kinase activity of the EGF receptor is enhanced by the expression of oncogenic 70Z-Cbl , 1997, Oncogene.
[94] J. Darnell,et al. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.
[95] R. Weinberg,et al. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene , 1984, Nature.
[96] A. Zilberstein,et al. EGF induces tyrosine phosphorylation of phospholipase C-II: A potential mechanism for EGF receptor signaling , 1989, Cell.
[97] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[98] F. McCormick. Signal transduction. How receptors turn Ras on. , 1993, Nature.
[99] A. Bridges,et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. , 1994, Science.
[100] A. Ullrich,et al. Human β-nerve growth factor gene sequence highly homologous to that of mouse , 1983, Nature.
[101] Christian Wiesmann,et al. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor , 1999, Nature.
[102] J. Rossant,et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.
[103] Masatsugu Hori,et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[104] Philippe Soriano. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. , 1997, Development.
[105] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[106] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[107] C. Heldin,et al. Stimulation of tyrosine-specific phosphorylation by platelet-derived growth factor , 1982, Nature.
[108] B. Curry,et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.
[109] Philippe Soriano,et al. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. , 1994, Genes & development.
[110] David C. Lee,et al. TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice , 1993, Cell.
[111] K. Jarnagin,et al. The human insulin receptor cDNA: The structural basis for hormone-activated transmembrane signalling , 1985, Cell.
[112] A. Ullrich,et al. Critical Role of Calcium- dependent Epidermal Growth Factor Receptor Transactivation in PC12 Cell Membrane Depolarization and Bradykinin Signaling* , 1997, The Journal of Biological Chemistry.
[113] C. Basbaum,et al. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells , 2002, Nature Medicine.
[114] W. Rutter,et al. Structure of a mouse submaxillary messenger RNA encoding epidermal growth factor and seven related proteins. , 1983, Science.
[115] D. Engelman,et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer , 1997, The EMBO journal.
[116] David C. Lee,et al. Tumor Necrosis Factor-α Converting Enzyme (TACE) Regulates Epidermal Growth Factor Receptor Ligand Availability* , 2002, The Journal of Biological Chemistry.
[117] Stanley N. Cohen,et al. EFFECTS OF THE EXTRACT OF THE MOUSE SUBMAXILLARY SALIVARY GLANDS ON THE SYMPATHETIC SYSTEM OF MAMMALS * , 1960, Annals of the New York Academy of Sciences.
[118] D. Stern,et al. EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. , 1988, The EMBO journal.
[119] Brian Higgins,et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.
[120] E. Nice,et al. Mice with a null mutation of the TGFα gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation , 1993, Cell.
[121] L. Ellis,et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. , 1999, Cancer research.
[122] David C. Lee,et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. , 1999, Development.
[123] E. Wagner,et al. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants , 1992, Molecular and cellular biology.
[124] A. Ullrich,et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF , 1999, Nature.
[125] M. Heinrich,et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.
[126] J. Massagué. TGF-beta signal transduction. , 1998, Annual review of biochemistry.
[127] Rüdiger Klein,et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.
[128] A. Levitzki,et al. Epidermal-growth-factor-dependent activation of the src-family kinases. , 1994, European journal of biochemistry.
[129] E. Wagner,et al. Strain-dependent epithelial defects in mice lacking the EGF receptor. , 1995, Science.
[130] Lieve Moons,et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.
[131] J. Schlessinger,et al. Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3. , 1988, The EMBO journal.
[132] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] J. Feramisco,et al. Epidermal growth factor stimulates guanine nucleotide binding activity and phosphorylation of ras oncogene proteins , 1984, Nature.
[134] Jonathan A. Cooper,et al. Similar effects of platelet-derived growth factor and epidermal growth factor on the phosphorylation of tyrosine in cellular proteins , 1982, Cell.
[135] A. Ullrich,et al. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors , 1986, Nature.
[136] D. Goeddel,et al. Nucleotide sequence of human preproinsulin complementary DNA. , 1980, Science.
[137] T. Quinn,et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[138] A. Ullrich,et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.
[139] D. Givol,et al. Nucleotide sequence analysis identifies the human c-sis proto-oncogene as a structural gene for platelet-derived growth factor , 1984, Cell.
[140] Kuo-Fen Lee,et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.